On September 19, Jafron Group, together with Xinhuanet, hosted the “919 ESRD Day” public welfare launch event in Beijing. The conference brought together leading nephrologists from China and abroad, medical institutions, and representatives from public welfare organizations to focus on the living conditions and medical needs of more than 3 million ESRD patients worldwide. The event also explored standardized hemoadsorption treatment, medical insurance policy support, and full-cycle patient management.

Jafron Group Chairman Mr. Dong Fan stated that, over the past 23 years since its founding, the Group has remained committed to the R&D and promotion of hemoadsorption cartridges. Today, Jafron products are used in nearly 100 countries and regions and more than 8,000 hospitals worldwide.He emphasized, “By designating September 19 as ‘ESRD Day,’ we hope to mobilize all sectors of society to support patients—not only helping them ‘survive,’ but enabling them to ‘live well.’”During the launch, Prof. Claudio Ronco, Founder and President of the International Renal Research Institute of Vicenza (IRRIV), delivered a keynote speech. Meanwhile, Jafron Group, together with the China Population Welfare Foundation and Jafron sunshine Medical Foundation, announced three public welfare programs. The initiatives include donations of cash and medical supplies totaling 20 million RMB, benefiting patients across multiple regions of China.

Leading Chinese experts highlighted that hemoadsorption can effectively remove middle to large molecule toxins, helping to alleviate pruritus, sleep disorders, and other complications, thereby improving patients’ quality of life. The inclusion of this technology in China’s latest medical insurance reimbursement policy has also significantly reduced the financial burden on patients.

With the continued promotion of the “919 ESRD Day” public welfare initiative, China’s experience in hemoadsorption will further accumulate, and more clinical outcomes will be shared. Jafron will leverage this opportunity to accelerate the global recognition and adoption of hemoadsorption technology among ESRD patients worldwide.

Following the launch event, donations for the “Guarding the Lifeline · Jafron Sunshine Charity Action” were dispatched to hospitals nationwide. The donated items included YH01 Infrared Therapeutic Machine, designed to support arteriovenous fistula care, relieve puncture pain, and extend vascular access longevity.One patient remarked, “These supplies not only ease our pain—they bring us the light of hope.”
Mr. Dong affirmed that Jafron will continue to support patient needs and provide strong, long-term assistance so that every patient may live with dignity.